(Q38183889)

30 August 2017

title

The discovery and development of cyclooxygenase-2 inhibitors as potential anticancer therapies (English)

1 reference

30 August 2017

Mohsen Vosooghi

1

1 reference

30 August 2017

Mohsen Amini

series ordinal

2

1 reference

30 August 2017

language of work or name

English

0 references

publication date

3 February 2014

1 reference

Expert Opinion on Drug Discovery

30 August 2017

published in

1 reference

30 August 2017

volume

9

1 reference

30 August 2017

issue

3

1 reference

30 August 2017

page(s)

255-267

1 reference

A randomized trial of aspirin to prevent colorectal adenomas

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Aspirin and the risk of colorectal cancer in relation to the expression of COX-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Inhibition of NF-kappa B by sodium salicylate and aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Sodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

COX inhibitors and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Inhibition of COX-2 in colon cancer modulates tumor growth and MDR-1 expression to enhance tumor regression in therapy-refractory cancers in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Antiproliferative effects of COX-2 inhibitor celecoxib on human breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

COX-2 gene expression in colon cancer tissue related to regulating factors and promoter methylation status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

The Crosstalk of PTGS2 and EGF Signaling Pathways in Colorectal Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

COX-2: a target for colon cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

COX-2: a molecular target for colorectal cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Changes in gene expression contribute to cancer prevention by COX inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Aspirin as adjuvant therapy for colorectal cancer--reinterpreting paradigms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Aspirin use and risk of colorectal cancer according to BRAF mutation status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Epigenetic deregulation of the COX pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

PTGS2 (Cyclooxygenase-2) expression and survival among colorectal cancer patients: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

The role of prostaglandins and other eicosanoids in the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Aspirin and the prevention of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Apoptosis-associated signaling pathways are required for chemotherapy-mediated female germ cell destruction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

The Bcl-2 protein family: arbiters of cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

The relationship between bcl-2 expression and response to chemotherapy in acute leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Sulindac for polyposis of the colon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Cell-cycle dysregulation and anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Cyclin-dependent kinases and cell-cycle transitions: does one fit all?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Specific COX-2 inhibitor, meloxicam, suppresses proliferation and induces apoptosis in human HepG2 hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Selective inhibition of cyclooxygenase-2 suppresses the growth of pancreatic cancer cells in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Resveratrol-induced cyclooxygenase-2 facilitates p53-dependent apoptosis in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Induction but not inhibition of COX-2 confers human lung cancer cell apoptosis by celecoxib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Mediators of PGE2 synthesis and signalling downstream of COX-2 represent potential targets for the prevention/treatment of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Resistance of prostate cancer cell lines to COX-2 inhibitor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Overexpression of ELAV-like protein HuR is associated with increased COX-2 expression in atrophy, high-grade prostatic intraepithelial neoplasia, and incidental prostate cancer in cystoprostatectomies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Inhibition of cyclooxygenase (COX)-2 expression by Tet-inducible COX-2 antisense cDNA in hormone-refractory prostate cancer significantly slows tumor growth and improves efficacy of chemotherapeutic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

COX-2 is expressed in human pulmonary, colonic, and mammary tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

COX-2 induces IL-11 production in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Overexpression of COX-2 in celecoxib-resistant breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Carcinogenesis and cyclooxygenase: the potential role of COX-2 inhibition in upper aerodigestive tract cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

PGE(2) is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Prevention of urinary bladder cancer in the FHIT knock-out mouse with Rofecoxib, a Cox-2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Evaluation of anticancer effects of newly synthesized dihydropyridine derivatives in comparison to verapamil and doxorubicin on T47D parental and resistant cell lines in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

P-glycoprotein mediates celecoxib-induced apoptosis in multiple drug-resistant cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Targeting COX-2 expression by natural compounds: a promising alternative strategy to synthetic COX-2 inhibitors for cancer chemoprevention and therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Preparation of polylactide-co-glycolide nanoparticles incorporating celecoxib and their antitumor activity against brain tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Coxibs and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Safety of celecoxib in individuals allergic to sulfonamide: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Design, synthesis, and biological evaluation of substituted 3-alkylthio-4,5-diaryl-4H-1,2,4-triazoles as selective COX-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Design, synthesis, cytotoxic evaluation and tubulin inhibitory activity of 4-aryl-5-(3,4,5-trimethoxyphenyl)-2-alkylthio-1H-imidazole derivatives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Doxorubicin-loaded PLGA nanoparticles by nanoprecipitation: preparation, characterization and in vitro evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.883377

10.1517/17460441.2014.883377

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference